Brokerages Set Novadaq Technologies Inc. (NVDQ) PT at $12.00

Novadaq Technologies Inc. (NASDAQ:NVDQ) (TSE:NDQ) has been assigned a consensus rating of “Hold” from the sixteen ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and two have given a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $12.00.

Several research firms have recently commented on NVDQ. Royal Bank of Canada reiterated a “hold” rating and set a $11.75 price objective on shares of Novadaq Technologies in a research note on Friday, September 1st. Canaccord Genuity restated a “hold” rating and set a $11.75 target price on shares of Novadaq Technologies in a research report on Friday, September 1st. BidaskClub upgraded shares of Novadaq Technologies from a “strong sell” rating to a “sell” rating in a research report on Tuesday, August 22nd. Zacks Investment Research upgraded shares of Novadaq Technologies from a “sell” rating to a “hold” rating in a research report on Friday, August 18th. Finally, Northland Securities restated a “hold” rating and set a $11.75 target price on shares of Novadaq Technologies in a research report on Monday, August 14th.

Several large investors have recently made changes to their positions in the business. Broadfin Capital LLC purchased a new stake in shares of Novadaq Technologies in the 2nd quarter valued at approximately $11,720,000. CNH Partners LLC purchased a new position in shares of Novadaq Technologies in the 2nd quarter valued at $7,340,000. State Street Corp grew its position in shares of Novadaq Technologies by 42.7% in the 2nd quarter. State Street Corp now owns 38,678 shares of the medical research company’s stock valued at $453,000 after buying an additional 11,578 shares during the last quarter. Janus Henderson Group PLC purchased a new position in shares of Novadaq Technologies in the 2nd quarter valued at $32,663,000. Finally, Goldman Sachs Group Inc. grew its position in shares of Novadaq Technologies by 2,035.3% in the 2nd quarter. Goldman Sachs Group Inc. now owns 1,814,404 shares of the medical research company’s stock valued at $21,265,000 after buying an additional 1,729,431 shares during the last quarter. 75.38% of the stock is currently owned by institutional investors.

WARNING: This piece was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.chaffeybreeze.com/2017/09/19/brokerages-set-novadaq-technologies-inc-nvdq-pt-at-12-00.html.

Shares of Novadaq Technologies (NASDAQ NVDQ) traded up inf% during midday trading on Friday, reaching $11.75. 395,280 shares of the company’s stock traded hands. The stock’s market capitalization is $679.41 million. The firm’s 50-day moving average price is $11.68 and its 200 day moving average price is $9.03. Novadaq Technologies has a 1-year low of $5.84 and a 1-year high of $12.74.

About Novadaq Technologies

NOVADAQ Technologies Inc is a medical device company. The Company primarily develops, manufactures and markets real-time fluorescence imaging products that are designed for use by surgeons in the operating room and other clinical settings where open and minimally invasive surgery or interventional procedures are performed.

Analyst Recommendations for Novadaq Technologies (NASDAQ:NVDQ)

Receive News & Ratings for Novadaq Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novadaq Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply